API | menacwy conjugate vaccine

menacwy conjugate vaccine Report issue

Vaccine Approved ^FDA

AACT

Active Ingredient History

NOW

Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanisms of Action: Missing data
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

acwyvax | conjugated meningococcal acwy-tt | group c meningococcal polysaccharide-tetansu toxoid conjugate | gsk3536820a | menabcwy | menactra | menacwy | menacwy conjugate vaccine | menacwy-crm | menacwy-crm197 | menacwy-ps | menacwy vaccine | menc-tt | meningococcal group a, c, w-135 and y conjugate vaccine | meningococcal polysaccharide diphtheria toxoid conj. | meningococcal polysaccharide (serogroups a, c, y and w-135) diphtheria toxoid conjugate vaccine | meningococcal polysaccharide tetanus protein conjugate | neisseria meningitidis serogroup a polysaccharide conjugated to tetanus toxoid / neisseria meningitidis serogroup c polysaccharide conjugated to tetanus toxoid /neisseria meningitidis serogroup w-135 polysaccharide conjugated to tetanus toxoid / neisseria meningitidis serogroup y polysaccharide conjugated to tetanus toxoid

Organizations (38)

Research & Development (38)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (37)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (37)

Chickenpox (Phase 3)

Coronavirus (Phase 3)

Diarrhea (Phase 2)

Diphtheria (Phase 4)

Diphtheria-Tetanus-Pertussis Vaccine (Phase 3)

Dysentery, Bacillary (Phase 1/Phase 2)

Encephalitis, Japanese (Phase 3)

Haemophilus influenzae (Phase 4)

Haemophilus influenzae type b (Phase 3)

Healthy Volunteers (Phase 3)

Hemorrhagic Fever, Ebola (Phase 2)

Hepatitis B (Phase 3)

HIV (Phase 4)

HIV Infections (Phase 4)

Immunization (Phase 4)

Influenza, Human (Phase 4)

Malaria (Phase 2)

Measles (Phase 3)

Meninges (Phase 3)

Meningitis (Phase 4)

Meningitis, Meningococcal (Phase 4)

Meningococcal Infections (Phase 4)

Meningococcal Vaccines (Phase 3)

Multiple Sclerosis (Phase 2)

Mumps (Phase 3)

Neisseria meningitidis (Phase 3)

Neoplasms, Glandular and Epithelial (Phase 3)

Papillomavirus Infections (Phase 3)

Pertussis Vaccine (Phase 4)

Pneumococcal Infections (Phase 3)

Rabies (Phase 3)

Rubella (Phase 3)

Sepsis (Phase 4)

Tetanus (Phase 4)

Typhoid Fever (Phase 3)

Whooping Cough (Phase 4)

Yellow Fever (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 155
# of Trial Organizations: 38

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue